An interventional study of Qigong Exercises in Substance Use Disorder (SUD), Anxiety and Depression, sponsored by Uskudar University. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-02.
Sponsored by Uskudar University · Not applicable, Interventional, and Supportive care
Patients receiving inpatient treatment for substance use disorder may experience anxiety and depressive symptoms. Qigong is a mind-body exercise that combines gentle movements, breathing techniques, and relaxation. This study aimed to evaluate the effects of Qigong exercises on anxiety and depression levels. The study was conducted as a single-blind, randomized controlled trial. Patients meeting the predefined eligibility criteria were randomly assigned to either the intervention group or the control group. The intervention group participated in Shibashi Qigong exercises four times a week for three weeks (12 sessions in total), while the control group did not receive Qigong exercises. Both groups continued their usual treatments. Anxiety and depression levels were assessed using the State-Trait Anxiety Inventory (STAI) and the Beck Depression Inventory (BDI) at three time points: before the intervention, immediately after the three-week exercise program, and one week after its completion.
2,238 studies on the registry are indexed under Substance-Related Disorders; 409 are open to participants now.
This study's enrollment of 70 is below the median of 108 across 1,840 interventional studies indexed under Substance-Related Disorders.
Browse Substance-Related Disorders studies →Uskudar University is the lead sponsor of 170 studies on the registry; 36 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Participants in this group received Qigong exercises four times per week for three weeks (12 sessions in total), while continuing their usual treatments.
Behavioral: Qigong Exercises
Participants in this group continued their usual treatments without receiving Qigong exercises during the study.
The intervention consisted of a standardized Shibashi Qigong exercise program delivered in 40-minute group sessions, four times per week for three weeks, for a total of 12 sessions. Each session began with a 5-minute warm-up and 5 minutes of breathing exercises, followed by 10 minutes of relaxation movements. The next 10 minutes included free spinal movements, clockwise and counterclockwise horizontal rotations, side-to-side swaying, and simple spinal exercises. Each session concluded with 10 minutes of cool-down and progressive relaxation.
Change in Trait Anxiety Scores Measured by the State-Trait Anxiety Inventory (STAI-II)
Trait anxiety was assessed using the Trait Anxiety subscale of the State-Trait Anxiety Inventory (STAI-II), developed by Spielberger et al. The STAI-II measures an individual's general tendency to experience anxiety, regardless of specific situations or circumstances. The scale consists of 20 items rated on a four-point Likert scale. Total scores range from 20 to 80, with higher scores indicating greater trait anxiety.
Time frame: Baseline, Week 3 (immediately post-intervention), and Week 4 (one-week follow-up)
Change in Depression Scores Measured by the Beck Depression Inventory (BDI)
Depression levels were assessed using the Beck Depression Inventory (BDI), developed by Beck et al. The BDI is a 21-item self-report instrument designed to assess the severity of depressive symptoms. Each item is scored on a four-point scale ranging from 0 to 3. Total scores range from 0 to 63, with higher scores indicating greater severity of depressive symptoms.
Time frame: Baseline, Week 3 (immediately post-intervention), and Week 4 (one-week follow-up)
Plan to share: No — Individual participant data will not be shared to protect participant privacy and confidentiality.
No publications or documents are linked to this record.
Ran from Mar 2025 to primary completion in Dec 2025, 9 months.
Of 814 non-industry interventional studies with no phase under Substance-Related Disorders, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 53. This study's 9 months is below that.
Counting every sponsor, half of 854 studies reached it within 34 months; a quarter within 17 and three quarters within 53.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
This study is completed, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.